All In Biotech

Drug Trial Radar · NCT01241552

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)

Last checked: Nov 19, 2026Latest source record: Sep 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,452 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,452

Actual

Start

Oct 10, 2011

Primary completion

Dec 9, 2014

Study completion Dec 9, 2014

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate whether: 1) treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 or MK-3415, 2) treatment with MK-3415A, MK-6072, or MK-3415, in addition to SOC antibiotic therapy will decrease CDI recurrence as compared to placebo, and 3) MK-3415A, MK-6072, and MK-3415 will be generally well tolerated in participants receiving SOC therapy for CDI as compared to placebo.

Conditions

  • Clostridium Difficile Infection

Interventions

  • MK-3415Biological

    A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)

  • MK-6072Biological

    A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)

  • MK-3415ABiological

    A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)

  • PlaceboBiological

    A single IV infusion of normal saline (0.9% sodium chloride)

  • SOCDrug

    Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clostridium Difficile Infection (CDI) RecurrenceTime frame: Up to 12 weeks
  2. Percentage of Participants With One or More Adverse Events (AEs) During 4 Weeks Following InfusionTime frame: Up to 28 days
  3. Percentage of Participants With Any Drug-related AE During 4 Weeks Following InfusionTime frame: Up to 28 days
  4. Percentage of Participants With Any Serious Adverse Events (SAEs) During 4 Weeks Following InfusionTime frame: Up to 28 days
  5. Percentage of Participants With Any Serious Drug-related Adverse Events During 4 Weeks Following InfusionTime frame: Up to 28 days
  6. Percentage of Participants Who Discontinued Study Medication Due to an AE During 4 Weeks Following InfusionTime frame: Up to 28 days
  7. Percentage of Participants With Infusion-specific AEsTime frame: Up to 24 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.